This HTML5 document contains 47 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n8http://localhost/temp/predkladatel/
n4http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n6http://linked.opendata.cz/ontology/domain/vavai/
n9http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n14http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216224%3A14110%2F06%3A00039991%21RIV10-MZ0-14110___/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n16http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216224%3A14110%2F06%3A00039991%21RIV10-MZ0-14110___
rdf:type
n6:Vysledek skos:Concept
dcterms:description
The primary endpoint of this study was to evaluate the efficacy (objective response rate; ORR) of combined chemotherapy with raltitrexed plus oxaliplatin as second-line treatment in patients with metastatic colorectal cancer (CRC). Secondary endpoints were overall survival (OS), time to progression (TTP) and toxicity (NCI-CTC criteria). The target population were patients with metastatic colorectal adenocarcinoma who progressed after first-line chemotherapy. Treatment consisted of raltitrexed 3 mg/m(2) as a 15-minute intravenous (IV) infusion followed 45 minutes later by oxaliplatin 130 mg/m(2) IV as a 2-h infusion on Day 1, repeated every 3 weeks until further disease progression (PD), unacceptable toxicity or the decision of the patient. A total of 51 patients, all with WHO performance status 0-2 received a median of 6 treatment cycles (range 1-11). After 3 cycles, 8 of the 47 evaluable patients (17%) had experienced an ORR, 28 patients (59. The primary endpoint of this study was to evaluate the efficacy (objective response rate; ORR) of combined chemotherapy with raltitrexed plus oxaliplatin as second-line treatment in patients with metastatic colorectal cancer (CRC). Secondary endpoints were overall survival (OS), time to progression (TTP) and toxicity (NCI-CTC criteria). The target population were patients with metastatic colorectal adenocarcinoma who progressed after first-line chemotherapy. Treatment consisted of raltitrexed 3 mg/m(2) as a 15-minute intravenous (IV) infusion followed 45 minutes later by oxaliplatin 130 mg/m(2) IV as a 2-h infusion on Day 1, repeated every 3 weeks until further disease progression (PD), unacceptable toxicity or the decision of the patient. A total of 51 patients, all with WHO performance status 0-2 received a median of 6 treatment cycles (range 1-11). After 3 cycles, 8 of the 47 evaluable patients (17%) had experienced an ORR, 28 patients (59.
dcterms:title
Raltitrexed plus oxaliplatin in the second-line treatment of metastatic colorectal cancer. Raltitrexed plus oxaliplatin in the second-line treatment of metastatic colorectal cancer.
skos:prefLabel
Raltitrexed plus oxaliplatin in the second-line treatment of metastatic colorectal cancer. Raltitrexed plus oxaliplatin in the second-line treatment of metastatic colorectal cancer.
skos:notation
RIV/00216224:14110/06:00039991!RIV10-MZ0-14110___
n3:aktivita
n17:Z
n3:aktivity
Z(MZ0MOU2005)
n3:cisloPeriodika
2
n3:dodaniDat
n16:2010
n3:domaciTvurceVysledku
n4:2912589 n4:4504135 n4:3503216 n4:9478426 n4:4160584 n4:1012010
n3:druhVysledku
n7:J
n3:duvernostUdaju
n18:S
n3:entitaPredkladatele
n14:predkladatel
n3:idSjednocenehoVysledku
496379
n3:idVysledku
RIV/00216224:14110/06:00039991
n3:jazykVysledku
n11:eng
n3:klicovaSlova
colorectal cancer; palliative chemotherapy; raltitrexed oxaliplatin
n3:klicoveSlovo
n5:palliative%20chemotherapy n5:raltitrexed%20oxaliplatin n5:colorectal%20cancer
n3:kodStatuVydavatele
SK - Slovenská republika
n3:kontrolniKodProRIV
[0D1413375900]
n3:nazevZdroje
Neoplasma
n3:obor
n15:FD
n3:pocetDomacichTvurcuVysledku
6
n3:pocetTvurcuVysledku
6
n3:rokUplatneniVysledku
n16:2006
n3:svazekPeriodika
53
n3:tvurceVysledku
Demlová, Regina Jarkovský, Jiří Kocáková, Ilona Dušek, Ladislav Vyzula, Rostislav Kiss, Igor
n3:zamer
n9:MZ0MOU2005
s:issn
0028-2685
s:numberOfPages
9
n8:organizacniJednotka
14110